Start with the claim and sample path
- UVGI
- Ultraviolet germicidal irradiation uses germicidal ultraviolet energy to inactivate microorganisms under defined exposure conditions. For testing, that definition must account for the target organism or surrogate, the air or surface path, the delivered exposure, and the recovery endpoint used to calculate reduction.1,5,7
The method should follow the question the data need to answer. A portable room air cleaner with a microbial reduction claim may call for an aerobiology chamber study. A duct module generally requires upstream and downstream single-pass bioaerosol sampling. A surface UV feature needs carrier or coupon recovery. A medical-device claim may require performance evidence that fits a 510(k) strategy, while a hybrid filter and UV device may need separate microbial and particle-removal evidence.1,3,5,6,8
| Sample path | Method question | Evidence usually needed |
|---|---|---|
| Bioaerosol chamber | Does the device reduce a generated airborne microbial challenge in a defined chamber? | Device-off decay, background checks, environmental records, viable or marker recovery, and reduction over time |
| Inline single pass | Does the UVGI module reduce the challenge between upstream and downstream sampling points? | Flow, residence time, lamp state, paired concentrations, sampler positions, and inactivation calculation |
| Irradiated surface | Does a defined UV exposure reduce microorganisms recovered from a carrier, coupon, or fixture? | Surface material, soil condition, delivered dose, exposure time, recovery control, and shadowing limits |
| Medical device context | Does the evidence support the intended use, predicate comparison, and labeling path? | Device description, indications, performance data, safety information, and substantial equivalence rationale |
| Filter plus UV comparison | What part of performance is particle removal and what part is microbial inactivation? | ASHRAE 52.2 or CADR-style particle data separated from bioaerosol or UVGI reduction data |
Bioaerosol chamber studies measure decay under controlled conditions
Chamber methods are useful when a product treats a room or enclosure rather than a single duct pass. ASTM E3273 describes an aerobiology chamber practice for assessing microbial survival, removal, or inactivation in indoor air, including treatment by physical agents such as ultraviolet light. AHAM AC-5-2023 addresses portable household air cleaners and key experimentally generated bioaerosols in a specified chamber.3,4
ASHRAE Standard 185.3-2024 provides a chamber method for commercial and industrial in-room air-cleaning devices and systems. ASHRAE states that the standard is not intended to conflict with or replace ANSI/AHAM AC-5 for portable residential air cleaners. That distinction matters when the study concerns a household device, a commercial in-room system, or a custom development comparison.1,3
- Define the chamber volume, mixing plan, generator output, environmental setpoints, device position, operating mode, and sampling schedule before challenge generation.3,4
- Run device-off or no-treatment controls so natural biological decay, wall loss, sampler loss, and background signal are separated from device effect.4
- State whether the endpoint is viable count, plaque count, molecular marker, particle proxy, or another assay, because those endpoints do not support the same claim language.3,4
- Keep household portable, commercial in-room, and building infection-control contexts separate unless the protocol explains why they are being compared.1,2,3
Inline single-pass testing compares bioaerosol concentrations upstream and downstream
For duct or enclosed-flow UVGI, the main question is what happens to a generated bioaerosol as it passes through the treatment zone once. ASHRAE Standard 185.1-2020 is the ASHRAE method for evaluating UVC lights used in air-handling units or ducts to inactivate airborne microorganisms. Its scope includes bioaerosol generation and upstream and downstream counting used to calculate inactivation efficiency.1
| Variable | Why it matters |
|---|---|
| Airflow and residence time | They set how long the airborne challenge remains in the irradiance zone. |
| Lamp state and warmup | Output can depend on lamp condition, operating mode, temperature, and age. |
| Sampler positions | Upstream and downstream samples must represent the same flow path without avoidable bypass or loss. |
| Organism or surrogate | Susceptibility and recovery differ, so the selected target defines what the result can support. |
| Background and blanks | They separate chamber or duct contamination, assay signal, and handling artifacts from UVGI effect. |
Surface UVGI requires dose, soil, and recovery controls
Surface UVGI does not measure the same endpoint as airborne inactivation. ASTM E3135-25 covers UVGI antimicrobial efficacy against microorganisms on carriers with simulated soil, including delivered UVGI dose and surface-recovery considerations. ASHRAE Standard 185.2-2020 focuses on ultraviolet lamps used on irradiated surfaces in HVAC&R units or ducts. ASHRAE Standard 185.4-2024 addresses in-room ultraviolet devices and systems used for microbial inactivation on surfaces in a test room.1,5
- Record surface material, inoculum condition, soil or contamination state, exposure distance, exposure angle, time, dose basis, and recovery method.5
- Use controls that distinguish UVGI inactivation from drying, poor recovery, carryover, assay inhibition, or fixture handling loss.5
- State whether the study represents HVAC irradiated surfaces, in-room exposed surfaces, device contact surfaces, or a custom surface fixture.1,5
- Treat radiation exposure, ozone, electrical safety, labeling, and occupied-room operation as separate safety questions unless they are explicitly included in the study scope.1,7
Regulatory and standards context shapes the evidence package
ASHRAE Standard 241 addresses infectious aerosol control in buildings, including requirements related to air-system design, installation, operation, and maintenance for reducing exposure to infectious aerosols. It provides useful context for equivalent clean airflow and infection-risk discussions, but it is not a stand-alone bench method for every UVGI device.2
FDA 510(k) context is relevant when a product is a medical device subject to premarket notification requirements and is not exempt. FDA describes a 510(k) as a premarket submission used to demonstrate substantial equivalence to a legally marketed predicate device before the product is marketed in the United States.6
ASHRAE 52.2 is a particle-removal standard for general ventilation air-cleaning devices and minimum efficiency reporting. It is not a UVGI bioaerosol inactivation method. For a hybrid filter and UV product, particle-removal data and microbial-reduction data should remain separate evidence streams unless the protocol supports a combined calculation.1,8
Build the validation plan around the reportable endpoint
- Name the endpoint first: chamber decay, single-pass inactivation, surface recovery, delivered dose, particle removal, regulatory performance data, or development screening.1,4,5,6,8
- Define the product state, including lamp type, device mode, fan speed, warmup, duty cycle, filter condition, enclosure, shielding, and maintenance state.1,7
- Select the organism, surrogate, or marker based on biosafety, susceptibility, recovery, intended claim, and whether viable recovery is required.3,4,5
- Separate efficacy, particle filtration, ozone or by-product, radiation safety, and regulatory-submission questions so the final report does not overstate the test scope.1,6,7,8
ARE Labs scopes UVGI studies by mapping the intended claim to the sample path and then selecting the chamber, duct, surface, organism, controls, exposure records, and report outputs. That keeps a bioaerosol chamber result, an inline single-pass result, a surface coupon result, and a regulatory performance package from being treated as interchangeable evidence.1,3,4,5,6